Search

This study investigates the antiviral efficacy of chitosan‐stabilized silver nanoparticles (AgNPs) against the Foot‐and‐Mouth Disease virus (FMDV), a highly contagious pathogen affecting cloven‐hoofed animals. In vitro experiments demonstrated that AgNPs effectively inhibited FMDV replication in a dose‐dependent manner. At a concentration of 1.56 μg/ml, AgNPs exhibited no cytotoxicity to baby hamster kidney 21 (BHK21) cells while achieving complete deactivation of FMDV at a titer of 103 TCID50 and inhibiting viral growth at a titer of 104 TCID50. These findings suggest the potential of silver nanoparticles as a novel disinfectant for controlling FMDV transmission and preventing disease outbreaks. [ABSTRACT FROM AUTHOR]

[Display omitted] • Pt/WO 3 was synthesized by dry plasma reduction. • 92.8 % removal efficiency of tetracycline under 1 kW/m2 was obtained. • The mineralization and possible degradation pathways of tetracycline are studied. • Tetracycline degradation kinetics are investigated. By using the dry plasma reduction method, Pt nanoparticles were successfully immobilized into WO 3 to fabricate a Pt/WO 3 composite catalyst and its application as an efficient photocatalysis in solar-driven degradation of Tetracycline (TTC). As a result, Pt nanoparticles (∼5nm) are uniform and well-distributed on the surface of WO 3. The bandgap of Pt/WO 3 is slightly lower than that of WO 3. The optimized TTC degradation efficiency reached 76.62 % and 92.58 % under visible light and 1-sun irradiation, respectively. The mineralization study further proved that at the optimum operational parameters, only 53.68 % and 71.38 % of TTC compounds were decomposed completely into inorganic ones under compact light and 1-sun irradiation, respectively. The transformation process of TTC showed that holes and hydroxyl radicals are the main agents for TTC degradation. The removal percentage declined by 6 % after seven consecutive cycles, showing high reusability, full-scale, and practical application of Pt/WO 3 material in organic compound treatment. [ABSTRACT FROM AUTHOR]